32682-99-8

Basic information

• Product Name: 1H-Imidazole-4-carboxylic acid, 2-phenyl-, methyl ester
• CAS NO: 32682-99-8
• Molecular Formula: C11H10N2O2
• Molecular Weight: 202.213
• Mol File: 32682-99-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Imidazole-4-carboxylic acid, 2-phenyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-4-carboxylic acid, 2-phenyl-, methyl ester(32682-99-8)
• EPA Substance Registry System: 1H-Imidazole-4-carboxylic acid, 2-phenyl-, methyl ester(32682-99-8)

Safety Data

• Hazardous Substances Data: 32682-99-8(Hazardous Substances Data)

Usage

Heterocyclic compound

Imidazole is a five-membered ring structure with 2 nitrogen atoms This makes the compound a heterocyclic aromatic compound, which is a type of organic compound with a ring structure containing at least one heteroatom.

Methyl ester

The carboxylic acid group is esterified with a methyl group This means that the compound has an ester functional group (R-COO-R') derived from the reaction of a carboxylic acid and an alcohol, in this case, methanol.

Derivative of imidazole

The compound is derived from imidazole This indicates that the compound is a modified version of the parent molecule, imidazole, which is a common structural motif in many biologically active molecules.

Potential pharmaceutical applications

The compound may be used in the development of drugs and therapeutic agents This suggests that the compound has properties that could be beneficial in treating diseases or medical conditions.

Use in organic synthesis and chemical research

The compound can be used as a building block or reagent in the synthesis of other organic compounds This means that the compound can be used to create new molecules with various applications.

Hazardous effects

Caution should be taken with this compound as it may have hazardous effects if mishandled or improperly used This indicates that the compound can pose risks to human health or the environment if not handled or used correctly.

Upstream product

• 33469-36-2 2-phenyl-5-(trifluoromethyl)-1H-imidazole 
• 67-56-1 methanol 
• 100-52-7 benzaldehyde 
• 922-67-8 propynoic acid methyl ester 
• 613-92-3 N-hydroxybenzenecarboximidamide 
• 32682-97-6 methyl 3-{[(amino(phenyl)methylene)amino]oxy}acrylate 
• 77498-98-7 2-phenyl-1H-imidazole-4-carboxylic acid 
• 613-92-3 N-hydroxybenzamidine 
• 1181818-57-4 C₁₁H₁₂N₂O₂ 
• 97602-42-1 methyl (E)-3-(5-phenyltetrazol-1-yl)propenoate 
• 97602-43-2 methyl (Z)-3-(5-phenyltetrazol-1-yl)propenoate 

Downstream Products

• 746671-41-0 methyl 1-methyl-2-phenyl-1H-imidazole-4-carboxylate 
• 235789-66-9 methyl 1-(4-amino-3-methylphenyl)-2-phenylimidazole-4-carboxylate 
• 235789-70-5 methyl 5-chloro-1-(3-methylphenyl)-2-phenylimidazole-4-carboxylate 
• 235789-65-8 methyl 1-(4-aminophenyl)-2-phenylimidazole-4-carboxylate 
• 235789-68-1 methyl 1-(3-methylphenyl)-2-phenylimidazole-4-carboxylate 
• 235789-69-2 methyl 5-chloro-1,2-diphenylimidazole-4-carboxylate 
• 235789-67-0 methyl 1,2-diphenylimidazole-4-carboxylate 
• 235789-64-7 methyl 1-(3-methyl-4-nitrophenyl)-2-phenylimidazole-4-carboxylate 
• 235789-63-6 methyl 1-(4-nitrophenyl)-2-phenylimidazole-4-carboxylate 

Relevant articles and documents

PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

HETEROARYL INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.